Evidence map›Paper›PMID 34071212›Full record

ArticleFoods (Basel, Switzerland)2021

Extending the Lipidome Coverage by Combining Different Mass Spectrometric Platforms: An Innovative Strategy to Answer Chemical Food Safety Issues.

Jérémy Marchand, Yann Guitton, Estelle Martineau, Anne-Lise Royer, David Balgoma, Bruno Le Bizec, Patrick Giraudeau, Gaud Dervilly

Abstract read
In one paragraph

Article in Foods (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Protective Mechanism ofFoods (Basel, Switzerland) · 2022
    Article
  3. Novel Analytical Methods in Food Analysis.Foods (Basel, Switzerland) · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jérémy MarchandLABERCA, Oniris, INRAE, 44307 Nantes, France.
Yann GuittonLABERCA, Oniris, INRAE, 44307 Nantes, France.ORCID 0000-0002-4479-0636
Estelle MartineauCEISAM UMR 6230, Université de Nantes, CNRS, 44000 Nantes, France.
Anne-Lise RoyerLABERCA, Oniris, INRAE, 44307 Nantes, France.
David BalgomaLABERCA, Oniris, INRAE, 44307 Nantes, France.
Bruno Le BizecLABERCA, Oniris, INRAE, 44307 Nantes, France.ORCID 0000-0002-0600-5895
Patrick GiraudeauCEISAM UMR 6230, Université de Nantes, CNRS, 44000 Nantes, France.ORCID 0000-0001-9346-9147
Gaud DervillyLABERCA, Oniris, INRAE, 44307 Nantes, France.ORCID 0000-0002-1867-0008

Funding

Conseil Régional des Pays de la Loire LIPIDOTOOL
6 · The paper itself

Abstract

From a general public health perspective, a strategy combining non-targeted and targeted lipidomics MS-based approaches is proposed to identify disrupted patterns in serum lipidome upon growth promoter treatment in pigs. Evaluating the relative contributions of the platforms involved, the study aims at investigating the potential of innovative analytical approaches to highlight potential chemical food safety threats. Serum samples collected during an animal experiment involving control and treated pigs, whose food had been supplemented with ractopamine, were extracted and characterised using three MS strategies: Non-targeted RP LC-HRMS; the targeted Lipidyzer™ platform (differential ion mobility associated with shotgun lipidomics) and a homemade LC-HRMS triglyceride platform. The strategy enabled highlighting specific lipid profile patterns involving various lipid classes, mainly in relation to cholesterol esters, sphingomyelins, lactosylceramide, phosphatidylcholines and triglycerides. Thanks to the combination of non-targeted and targeted MS approaches, various compartments of the pig serum lipidome could be explored, including commonly characterised lipids (Lipidyzer™), triglyceride isomers (Triglyceride platform) and unique lipid features (non-targeted LC-HRMS). Thanks to their respective characteristics, the complementarity of the three tools could be demonstrated for public health purposes, with enhanced coverage, level of characterization and applicability.

Indexed as

LC-HRMSlipidomicsLipidyzer™ractopamineserumβ-agonist

Identifiers

PMID34071212
PMCPMC8230090

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.